There can be little doubt that hepatocellular carcinoma (HCC) is a growing problem in the United States and even more so on a global scale. Examination of the literature for treatment of HCC shows that the roadside is littered with the debris of failed clinical trials of all sorts, and the limitations of existing therapies become all too obvious. This state of things underscores the observation that, whenever there are many ways to do something, it is because none of them work really well. There is a bright spot in this situation, however.
展开▼
